Nintedanib (BIBF 1120) in Mesothelioma (Q65361966)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Nintedanib (BIBF 1120) in Mesothelioma |
clinical trial |
Statements
LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma (English)
0 references
19 September 2013
0 references
16 March 2018
0 references
545
0 references
18 year
0 references